Global Hemophilia Market: Latest trends, Growth & Insights until 2025| Key Players Novo Nordisk, Pfizer, Inc., Bayer AG

The global hemophilia market is expected to grow at growth rate of 5.3% to reach USD 15.5 billion by 2025. This comprehensive study reveals the market estimate numbers for different market segments. Along with that, the study covers qualitative insights, strategic bench-marking and thorough competitive landscaping in the report spreading over 120 pages.

Over the eight years to 2016, revenue for the hemophilia industry is anticipated trend higher. Increasing neonatal population coupled with favorable government initiatives for the development of this market is anticipated to drive the demand for hemophilia diagnosis across the world. For example, the World Population Meter stated that more than 88.0 billion newborns were reported in 2015 resulting in about 250 births per minute. In addition, increasing adoption of prophylaxis and emergence of more effective drugs for this bleeding disorder treatment augment the industry growth to great extent.

For instance, in January 2016, Octapharma received U.S. FDA approval for the Nuwiq for use in perioperative, and routine prophylaxis to reduce bleeding episodes caused due to Hemophilia A. The company is also working on two new molecules named NuProtect and NuPreviq which are under clinical trial and would be commercially available soon post investigation. Other factors such as increasing pipeline therapeutics, technological advancements and expanding medical tourism support the industry growth to some extent. On contrary, high cost coupled with low awareness on available diagnosis options hamper the market growth over the forecast period.

To request free sample copy:
https://www.analystviewmarketinsights.com/request_sample/av180/

Key Takeaways:
- Of the different hemophilia types, A category accounted for the major share, i.e. 69.3% share of the total market. This segment is likely to dominate the worldwide market over the future period
- The on-demand treatment industry is in the mature phase and is projected to grow with a significant growth rate over the foreseeable future.
- Among therapy segment, gene therapy is considered to be the lowest revenue generating segment, however, is growing with the highest growth rate over the forecast period. Most of these therapies are under pre-clinical stages and is expected to experience great demand in future, owing to its ability to completely eradicate hemophilia.
- The industry exhibits a high level of competition. Since the market is mature, the barriers to entry are relatively low. Companies such as Bayer AG, Novo Nordisk, Pfizer, Inc., Biogen, and Baxalta are extensively profiled in the report.
- Key players are increasingly investing in research and development activities to develop novel therapeutics for this disorder. For example, in March 2016, Baxalta commenced the clinical trial for BAX 826, indicated to be used in the treatment of Hemophilia A. This molecule is the second product to be developed based on extended half-life therapy.

Browse full report with in-depth ToC on “Hemophilia Market, By Types (Hemophilia A, Hemophilia B, and Hemophilia C), By Treatment (On-demand and Prophylaxis), By Therapy and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at
https://www.analystviewmarketinsights.com/report-highlight-hemophilia-market/

The scope of this report covers the market by its major segments, which include as follows:
Market, by types: Hemophilia A, Hemophilia B, Hemophilia C, Others; Market, by treatment: On-demand, Prophylaxis; Market, by therapy; Immune Tolerance Induction (ITI) therapy, Replacement therapy, Gene therapy;
Market, by Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa and Rest of the World; Market, by Country: U.S., Canada, Germany, France, India, China;

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles of companies):
Novo Nordisk
Bayer AG
Pfizer, Inc.
Baxalta
Biogen

Key benefits of the report:
• The report presents macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
• Thorough analysis of relevant statistical data to estimate the market paradigms
• Exceptional understanding of region and country specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
• Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Find out more by getting in touch: https://www.analystviewmarketinsights.com/get-in-touch/

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: sales@analystviewmarketinsights.com
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)
Web: www.analystviewmarketinsights.com

This release was published on openPR.